Log In or Create Account

CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact

Advanced Search

CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Considerations for Clinical Trials in Bacteriophages

Considerations for Clinical Trials in Bacteriophages

Considerations for Clinical Trials in Bacteriophages
Vance Fowler

On-Demand Webcast

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

Home
Activities
Resources
About
Contact
Login
Careers
Donate
Website Policies

© 2026 International Antiviral Society–USA. All Rights Reserved.

CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Practice Question of the Week

May 11, 2026: Semaglutide Effects on Muscle Mass and Physical Function

In the SLIM LIVER (Study of Semaglutide for Non-Alcoholic Fatty Liver Disease [NAFLD], a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk) study, which of the following was observed regarding changes in muscle mass and physical function as assessed by the chair rise test?
- A. Decreased psoas muscle mass with reduced functional performance
- B. Increased psoas muscle mass with improved functional performance
- C. Decreased psoas muscle mass with preserved functional performance
- D. Increased psoas muscle mass with preserved functional performance

View the On-Demand Webinar

View Archived Questions